Updated:
ElevateBio
ElevateBio was founded in 2017 to build the scaled manufacturing infrastructure that cell and gene therapy developers need but rarely own.
ElevateBio
ElevateBio was founded in 2017 to build the scaled manufacturing infrastructure that cell and gene therapy developers need but rarely own. The firm operates as an advanced therapy contract development and manufacturing organization (CDMO), backed by a syndicate of life sciences specialists: MPM Capital co-founder Ansbert Gadicke sits on the board alongside representatives from F2 Ventures, SoftBank, Matrix Capital Management, and The Invus Group. Strategy flows through a stack that spans CRISPR-based gene editing tools, discovery services, process development, and commercial cGMP manufacturing. The firm works across multiple modalities — cell therapies, viral vectors, mRNA, and gene editing — and offers services from early candidate engineering through BLA filing support. Its "BaseCamp" facility in Waltham, Massachusetts, and a second site in Pittsburgh co-locate science, analytics, and production to eliminate hand-offs between stages. The geographic footprint is concentrated in the US, with additional satellite offices in Menlo Park, Palo Alto, Boston, and New York. Team scale is not publicly disclosed, but the leadership bench mixes CDMO veterans with drug-developer experience: Chief Technology Officer Michael Paglia leads the closed, digital manufacturing platform, while Chief Scientific Officer Amy Pooler heads the gene editing and discovery services. Recent operational expansion includes the continued build-out of BaseCamp Pittsburgh, which the firm positions as a model for domestic biomanufacturing. In 2025, ElevateBio made CNBC's Disruptor 50 list for the fourth time, underscoring its technology investment thesis. Unlike traditional CDMOs that compete primarily on batch pricing, ElevateBio has wired automation and AI into its operating model — not as a discrete product, but as a permanent cost-of-goods lever. That technical spine, combined with a sponsor-side-experienced team that runs integrated programs from target identification to commercial supply, shapes a different value proposition: the firm underwrites process innovation so its partners do not have to pause development to change vendors.
General information
Firm type
Single Family Office
Year founded
2017
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Waltham
Corporate office
225 Wyman Street, Waltham, MA 02451, United States
Additional offices
BaseCamp, 200 Smith St, Waltham, MA 02451 · BaseCamp Pittsburgh, Pittsburgh, PA · Menlo Park, CA · Palo Alto, CA · Boston, MA · New York, NY
Principals
Christopher Murphy
Chief Executive Officer
David Hallal
Executive Chairman
Michael Paglia
Chief Technology Officer
Amy Pooler
Chief Scientific Officer
Bhakti Bhargava
Chief Financial Officer
Larry Lockwood
Chief Commercial Officer
Sector focus
Frequently asked questions
How does ElevateBio structure its platform differently from a traditional CDMO?
ElevateBio operates as a technology company first, investing continuously in automation, AI-assisted design, and process innovation rather than treating technology as a one-time capex event. It co-locates science, process development, and manufacturing within its BaseCamp facilities to eliminate the friction of multi-vendor hand-offs. This integrated model is designed so that efficiency gains achieved in development carry directly through to commercial-scale production.
What is the relationship between ElevateBio SoftBank and its other institutional backers?
SoftBank is a significant investor via Managing Partner Navneet Govil, who holds a board seat. The investor consortium also includes MPM Capital (Ansbert Gadicke, co-founder, on the board), F2 Ventures, Matrix Capital Management, and The Invus Group. These relationships give ElevateBio a board with deep operational and financial ties to the biopharma ecosystem rather than a single-family-office governance model.
Does ElevateBio hold an equity stake in the therapies its partners develop?
The firm does not publicly disclose whether its partnership models include equity participation. Its marketed structure is a fee-for-service CDMO relationship, but the presence of venture-style institutional backers — including funds accustomed to hybrid compensation — means specific economics may vary by partner and program stage.
What therapeutic modalities does ElevateBio's platform support?
The firm operates across four core modalities: cell therapies, viral vectors, mRNA therapeutics and vaccines, and gene editing. Its gene editing capabilities extend from target identification through therapeutic candidate optimization, supported by next-generation sequencing and custom analytical development for regulatory filings.
How does ElevateBio handle technology transfer when a program scales?
ElevateBio structures partnerships around a dedicated, cross-functional team that stays with a program from early development through technology transfer, clinical supply, and commercial manufacturing. The firm claims that this continuity avoids the delays and process rework that often occur when a sponsor transitions between separate development and commercial manufacturing organizations.
Who runs day-to-day investment and scientific decision-making at ElevateBio?
Chief Executive Officer Christopher Murphy leads the firm, with Chief Scientific Officer Amy Pooler directing the gene editing and discovery engine and Chief Technology Officer Michael Paglia overseeing the closed, digital manufacturing platform. Board oversight includes Executive Chairman David Hallal (CEO of Scholar Rock) and representatives from the core investor group.
Where does ElevateBio's manufacturing capacity sit geographically?
Primary manufacturing operations are at the BaseCamp facility in Waltham, Massachusetts. A second BaseCamp site is operational in Pittsburgh, which ElevateBio has promoted as a model for expanding domestic biomanufacturing capacity. Additional commercial and scientific offices are maintained in Menlo Park, Palo Alto, Boston, and New York.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: